(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 December 2009 (23.12.2009)

PCT

(10) International Publication Number
WO 2009/153589 A1

(51) International Patent Classification:
C07D 401/12 (2006.01) *C07D 413/14* (2006.01)
C07D 401/14 (2006.01) *A61K 31/4439* (2006.01)
C07D 405/14 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/GB2009/050675

(22) International Filing Date:
15 June 2009 (15.06.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/073,055 17 June 2008 (17.06.2008) US

(71) Applicant *(for all designated States except MG, US)*: **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(71) Applicant *(for MG only)*: **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BARLAAM, Bernard, Christophe** [FR/FR]; AstraZeneca Pharma, Z.I. La Pompell, BP 1050, F-51689 Reims, Cedex 2 (FR). **FOOTE, Kevin, Michael** [GB/GB]; AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **PLE, Patrick** [FR/FR]; AstraZeneca Pharma, Z.I. La Pompell, BP 1050, F-51689 Reims, Cedex 2 (FR).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; AstraZeneca AB, S-151 85 Södertälje (SE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2009/153589 A1

(54) **Title**: PYRIDINE COMPOUNDS



(I)

(57) **Abstract**: The present invention relates to compounds that inhibit of focal adhesion kinase function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases such as cancer.